Depending on the type of alternative payment models, it could be more difficult or easier for practices to find overlaps and participate in multiple models, said Mike Fazio, senior vice president of client services, Archway Health.
Depending on the type of alternative payment models, it could be more difficult or easier for practices to find overlaps and participate in multiple models, said Mike Fazio, senior vice president of client services, Archway Health.
Transcript
As the country moves to value-based care, the number of alternative payment models is growing, and many practices are participating in more than one. Are they having trouble balancing multiple models?
It depends on the model. So, OCM [Oncology Care Model] involves so much of the patient mix of OCM practices and because of the care transformation components of the program from the get-go it’s been an area of focus for anyone that’s in OCM.
In some of the other programs, like BPCI [Bundled Payments for Care Improvement] Advanced, there is intersection and overlap with other programs, like the ACO [accountable care organization] program, for example. And those models, thought, BPCI is a great avenue to incent specialists within a primary care model, like an ACO. So, it does differ.
But from an OCM perspective we see that participants are very focused and with the movement toward downside risk in OCM, for those practices that make that choice this fall, definitely more focus on OCM because of that. Whereas a one-sided model, it’s a different beginning than being in a risk-based model.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More